Pyrimidine derivatives useful as selective COX-2 inhibitors

Abstract

Methods of treating a subject suffering from a condition which is mediated by COX-2.

1 - 18 . (canceled)  
     
     
         19 . A method of treating a subject suffering from a condition which is mediated by COX-2 which comprises administering to said subject an effective amount of a compound of formula (I)  
       
         
           
           
               
               
           
         
       
       in which: 
 R 1  is selected from the group consisting of H, C 1-6 alkyl, C 1-2 alkyl substituted by one to five fluorine atoms, C 3-6 alkenyl, C 3-6 alkynyl, C 3-10 cycloalkylC 0-6 alkyl, C 4-12 bridged cycloalkyl, A(CR 4 R 5 ) n  and B(CR 4 R 5 ) n ;  
 R 2  is C 1-2 alkyl substituted by one to five fluorine atoms;  
 R 3  is selected from the group consisting of C 1-6 alkyl, NH 2  and R 7 CONH;  
 R 4  and R 5  are independently selected from H or C 1-6 alkyl;  
 A is an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R 6 ;  
 R 6  is selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 alkyl substituted by one more fluorine atoms, C 1-6 alkoxy, C 1-6 alkoxy substituted by one or more F, NH 2 SO 2  and C 1-6 alkylSO 2 ;  
 B is selected from the group consisting of  
                     
 R 7  is selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylOC 1-6 alkyl, phenyl, HO 2 CC 1-6 alkyl, C 1-6 alkylOCOC 1-6 alkyl, C 1-6 alkylOCO, H 2 NC 1-6 alkyl, C 1-6 alkylOCONHC 1-6 alkyl and C 1-6 alkylCONHC 1-6 alkyl; and  
 n is 0 to 4.  
 
     
     
         20 . A method of treating a subject suffering from an inflammatory disorder mediated by COX-2, which method comprises administering to said subject an effective amount of a compound of formula (I)  
       
         
           
           
               
               
           
         
       
       in which: 
 R 1  is selected from the group consisting of H, C 1-6 alkyl, C 1-2 alkyl substituted by one to five fluorine atoms, C 3-6 alkenyl, C 3-6 alkynyl, C 3-10 cycloalkylC 0-6 alkyl, C 4-12 bridged cycloalkl, A(CR 4 R 5 ) n and B(CR 4 R 5 ) n ;  
 R 2  is C 1-2 alkyl substituted by one to five fluorine atoms;  
 R 3  is selected from the group consisting of C 1-6 alkyl, NH 2  and R 7 CONH;  
 R 4  and R 5  are independently selected from H or C 1-6 alkyl;  
 A is an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R 6 ;  
 R 6  is selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 alkyl substituted by one more fluorine atoms, C 1-6 alkoxy, C 1-6 alkoxy substituted by one or more F, NH 2 SO 2  and C 1-6 alkylSO 2 ;  
 B is selected from the group consisting of  
                     
 R 7  is selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylOCO 1-6 alkyl, phenyl HO 2 CC 1-6 alkyl, C 1-6 alkylOCOC 1-6 alkyl, C 1-6 alkylOCO, H 2 NC 1-6 alkyl, C 1-6 alkylOCONHC 1-6 alkyl and C 1-6 alkylCONHC 1-6 alkyl; and  
 n is 0 to 4.  
 
     
     
         21 - 22 . (canceled)  
     
     
         23 . The method according to  claim 19 , wherein said subject is a human.  
     
     
         24 . The method according to  claim 20 , wherein said subject is a human.